2747915-92-8
Chemical Structure
(R)-Carvedilol-d4
Synonym(s): (R)-BM 14190-d4
- CAS No.: 2747915-92-8
- Formula:C24H22D4N2O4
- Molecular Weight:410.50
IUPAC Name: (R)-1-((9H-carbazol-4-yl)oxy)-3-((2-(2-methoxyphenoxy)ethyl-1,1,2,2-d4)amino)propan-2-ol
InChIKey: OGHNVEJMJSYVRP-QWCPZVJHSA-N
SMILES: O[C@H](CNC([2H])([2H])C([2H])([2H])OC1=CC=CC=C1OC)COC2=CC=CC(N3)=C2C4=C3C=CC=C4
Biological Activity: (R)-Carvedilol-d4 is deuterium labeled (R)-Carvedilol (HY-B0006C). (R)-Carvedilol ((R)-BM 14190) is the orally active R-isomer of Carvedilol (HY-B0006). (R)-Carvedilol has α-receptor blocking activity but no β-receptor blocking activity. (R)-Carvedilol inhibits spontaneous Ca2+ waves. (R)-Carvedilol inhibits stress-induced ventricular tachycardia and delays the development of UV-induced skin tumors and reduces their malignancy[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
(R)-Carvedilol-d4 | (R)-Carvedilol-d4 is deuterium labeled (R)-Carvedilol (HY-B0006C). (R)-Carvedilol ((R)-BM 14190) is the orally active R-isomer of Carvedilol (HY-B0006). (R)-Carvedilol has α-receptor blocking activity but no β-receptor blocking activity. (R)-Carvedilol inhibits spontaneous Ca2+ waves. (R)-Carvedilol inhibits stress-induced ventricular tachycardia and delays the development of UV-induced skin tumors and reduces their malignancy. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(R)-Carvedilol | 98.78% | (R)-Carvedilol ((R)-BM 14190) is the orally active R-isomer of Carvedilol (HY-B0006). (R)-Carvedilol has α-receptor blocking activity but no β-receptor blocking activity. (R)-Carvedilol inhibits spontaneous Ca2+ waves. (R)-Carvedilol inhibits stress-induced ventricular tachycardia and delays the development of UV-induced skin tumors and reduces their malignancy. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Wu T, et al. Protective effects of S-carvedilol on doxorubicin-induced damages to human umbilical vein endothelial cells and rats. J Appl Toxicol. 2019 Aug;39(8):1233-1244. [Content Brief]
- [3]. Zhang J, et al. Non-β-blocking R-carvedilol enantiomer suppresses Ca2+ waves and stress-induced ventricular tachyarrhythmia without lowering heart rate or blood pressure. Biochem J. 2015 Sep 1;470(2):233-42. [Content Brief]
- [4]. Sardar PK, et al. Oral delivery of the non-β-blocking R-carvedilol enantiomer for skin cancer chemoprevention in SKH-1 mice. AAPS Open. 2025;11:1. [Content Brief]
Keywords
